BridgeBio Pharma, Inc. Share-based Payment Arrangement, Expense
BridgeBio Pharma, Inc. (BBIO) reported Share-based Payment Arrangement, Expense of $44.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-10
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $44.52M, a 19.24% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $33.36M, a 13.52% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $34.89M, a 4.24% decline year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $35.26M, a 29.98% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for fiscal 2025 was $136.88M, a 20.21% increase from fiscal 2024.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for fiscal 2024 was $113.87M, a 1.00% decline from fiscal 2023.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for fiscal 2023 was $115.02M, a 22.58% increase from fiscal 2022.
- BridgeBio Pharma, Inc. share-based payment arrangement, expense for fiscal 2022 was $93.83M, a 11.13% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $44.52M 10-Q · filed 2026-08-10 | $77.89M 10-Q · filed 2026-08-10 | $112.78M derived: sum of 3 quarters · filed 2026-08-10 | $148.04M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $33.36M 10-Q · filed 2026-05-07 | $68.25M derived: sum of 2 quarters · filed 2026-05-07 | $103.52M derived: sum of 3 quarters · filed 2026-05-07 | $140.86M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $34.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $70.15M derived: sum of 2 quarters · filed 2026-02-24 | $107.49M derived: sum of 3 quarters · filed 2026-08-10 | $136.88M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $35.26M 10-Q · filed 2025-10-29 | $72.60M derived: sum of 2 quarters · filed 2026-08-10 | $101.99M 10-Q · filed 2025-10-29 | $138.43M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $37.34M 10-Q · filed 2026-08-10 | $66.73M 10-Q · filed 2026-08-10 | $103.16M derived: sum of 3 quarters · filed 2026-08-10 | $130.29M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $29.39M 10-Q · filed 2026-05-07 | $65.82M derived: sum of 2 quarters · filed 2026-05-07 | $92.95M derived: sum of 3 quarters · filed 2026-05-07 | $114.41M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $36.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $63.56M derived: sum of 2 quarters · filed 2026-02-24 | $85.02M derived: sum of 3 quarters · filed 2026-02-24 | $113.87M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $27.13M 10-Q · filed 2025-10-29 | $48.58M derived: sum of 2 quarters · filed 2025-10-29 | $77.43M 10-Q · filed 2025-10-29 | $114.56M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $21.45M 10-Q · filed 2025-08-05 | $50.30M 10-Q · filed 2025-08-05 | $87.43M derived: sum of 3 quarters · filed 2026-02-24 | $114.66M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $28.85M 10-Q · filed 2025-04-29 | $65.98M derived: sum of 2 quarters · filed 2026-02-24 | $93.21M derived: sum of 3 quarters · filed 2026-02-24 | $120.39M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $37.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $64.36M derived: sum of 2 quarters · filed 2026-02-24 | $91.54M derived: sum of 3 quarters · filed 2026-02-24 | $115.02M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $27.23M 10-Q · filed 2024-11-12 | $54.41M derived: sum of 2 quarters · filed 2024-11-12 | $77.88M 10-Q · filed 2024-11-12 | $100.47M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | $27.18M 10-Q · filed 2024-08-01 | $50.65M 10-Q · filed 2024-08-01 | $73.24M derived: sum of 3 quarters · filed 2025-02-20 | $91.89M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | $23.48M 10-Q · filed 2024-05-02 | $46.06M derived: sum of 2 quarters · filed 2025-02-20 | $64.72M derived: sum of 3 quarters · filed 2025-02-20 | $93.02M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | $22.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $41.24M derived: sum of 2 quarters · filed 2025-02-20 | $69.55M derived: sum of 3 quarters · filed 2025-02-20 | $93.83M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $18.66M 10-Q · filed 2023-11-02 | $46.96M derived: sum of 2 quarters · filed 2023-11-02 | $71.24M 10-Q · filed 2023-11-02 | $93.76M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $28.30M 10-Q · filed 2023-08-03 | $52.59M 10-Q · filed 2023-08-03 | $75.10M derived: sum of 3 quarters · filed 2024-02-22 | $91.23M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $24.28M 10-Q · filed 2023-05-04 | $46.79M derived: sum of 2 quarters · filed 2024-02-22 | $62.92M derived: sum of 3 quarters · filed 2024-02-22 | $94.96M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $22.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $38.64M derived: sum of 2 quarters · filed 2024-02-22 | $70.68M derived: sum of 3 quarters · filed 2024-02-22 | $105.57M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $16.13M 10-Q · filed 2022-11-03 | $48.16M derived: sum of 2 quarters · filed 2022-11-03 | $83.06M 10-Q · filed 2022-11-03 | $95.21M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $32.03M 10-Q · filed 2022-08-04 | $66.93M 10-Q · filed 2022-08-04 | $79.08M derived: sum of 3 quarters · filed 2023-02-23 | $96.78M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $34.90M 10-Q · filed 2022-05-05 | $47.04M derived: sum of 2 quarters · filed 2023-02-23 | $64.74M derived: sum of 3 quarters · filed 2023-02-23 | $83.13M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $29.84M derived: sum of 2 quarters · filed 2023-02-23 | $48.24M derived: sum of 3 quarters · filed 2023-02-23 | $58.46M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $17.70M 10-Q · filed 2021-11-04 | $36.09M derived: sum of 2 quarters · filed 2021-11-04 | $46.31M 10-Q · filed 2021-11-04 | $56.32M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $18.39M 10-Q · filed 2021-08-05 | $28.61M 10-Q · filed 2021-08-05 | $38.62M derived: sum of 3 quarters · filed 2022-02-25 | $44.40M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | $10.22M 10-Q · filed 2021-05-06 | $20.23M derived: sum of 2 quarters · filed 2022-02-25 | $26.01M derived: sum of 3 quarters · filed 2022-02-25 | $29.36M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $15.78M derived: sum of 2 quarters · filed 2022-02-25 | $19.14M derived: sum of 3 quarters · filed 2022-02-25 | $21.37M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $5.78M 10-Q · filed 2020-11-05 | $9.13M derived: sum of 2 quarters · filed 2020-11-05 | $11.37M 10-Q · filed 2020-11-05 | $14.48M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $3.36M 10-Q · filed 2020-08-11 | $5.59M 10-Q · filed 2020-08-11 | $5.52M 10-Q · filed 2019-08-14 | $8.70M derived: sum of 3 quarters · filed 2021-02-25 | $9.89M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.23M 10-Q · filed 2020-05-14 | $5.34M derived: sum of 2 quarters · filed 2021-02-25 | $6.53M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.30M derived: sum of 2 quarters · filed 2021-02-25 | $6.07M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.95M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $1.77M 10-Q · filed 2019-08-14 | ||||
| 2017-12-31 | $1.84M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |